First published · Last updated
Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis
A SAGE-published journal article presents a two-year cost analysis comparing bevacizumab-first treatment under a DRCR protocol AC with real-world physician treatment choices for diabetic macular edema. The item was published on 2024-09-14.
Categories: public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 4/10
- Geographic reach
- 1/10
- Global importance
- 2/10
- Impact magnitude
- 2/10
- Positivity
- 5/10
- Urgency
- 1/10
Why it matters
The article reports a multi-year cost comparison that is relevant to treatment decision-making for diabetic macular edema.

